Literature DB >> 33875946

Similar therapeutic effects of 125I seed radiotherapy and γ-ray radiotherapy on lacrimal gland adenoid cystic carcinoma.

Rui Liu1, Ji-Tong Shi1, Xin Ge1, Ben-Tao Yang1, Hong Zhang1, Jing-Xue Zhang1, Jian-Min Ma1.   

Abstract

AIM: To evaluate the survival outcomes of patients with lacrimal gland adenoid cystic carcinoma who underwent eye-sparing surgery combined with 125I seed implantation radiotherapy or local external γ-ray radiotherapy.
METHODS: In this retrospective comparative case series, the clinical records of 27 primary and 8 recurrent patients were reviewed. Univariate and multivariate analyses were used to identify risk factors associated with distant metastasis (DM), and the overall survival (OS) after the initial surgery was analyzed.
RESULTS: The median follow-up after radiotherapy was 36mo (range 6-120mo). At the last follow-up after radiotherapy, 26 (74.3%) patients had no evidence of disease, 7 (20%) patients had DM, 2 (5.9%) patients died of DM, and 1 patient with DM was lost to follow-up. Univariate analyses showed that duration of symptoms, bone destruction, T stage classification, and wide excision surgery were risk factors influencing DM (P<0.05). The 5-year and 10-year OS rates after the initial surgery were 95.8% and 79.9%, respectively. The 5-year DM-free survival and disease-free survival rates after radiotherapy were 66.4% and 52.7%, respectively.
CONCLUSION: 125I seed radiotherapy and local external γ-ray radiotherapy may have similar therapeutic effects in preventing DM. Patients with T1/T2 stage disease have a better prognosis than those with T3/T4 stage disease. International Journal of Ophthalmology Press.

Entities:  

Keywords:  125I seed radiotherapy; adenoid cystic carcinoma; lacrimal gland; surgical excision; γ-ray radiotherapy

Year:  2021        PMID: 33875946      PMCID: PMC8025165          DOI: 10.18240/ijo.2021.04.11

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  1 in total

1.  Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland.

Authors:  Jingxue Zhang; Xuejing Yan; Rui Liu; Shen Wu; Qian Liu; Jing Li; Jianmin Ma
Journal:  Cancer Manag Res       Date:  2022-03-06       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.